Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 372 participants.
Also called NCT03760991
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 372 participants
- Sponsor
- Registry
-
NCT03760991
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Argentina, Colombia, Egypt, Hong Kong SAR China, India, Indonesia, Lebanon, Malaysia, Peru, Philippines, Saudi Arabia, South Africa, Thailand, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT03760991. Allocation not applicable; no masking; primary purpose treatment. Start 2018-12-18 (actual); primary completion 2020-09-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin
- Acronym
- ARTEMIS-DM
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- INSULIN GLARGINE (U300)
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct03760991- Content hash
6f1caef8c4580dce8d9d7f2a1f6807500afc56f8cafb3f10842dcf3e8ff9d0c4